Richard Gonzalez, AP Images
AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?
Despite a bumpy takeoff, AbbVie has some big plans for Vraylar, the blockbuster schizophrenia and bipolar drug it snapped up from Allergan a couple of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
